264 related articles for article (PubMed ID: 25042790)
1. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2014 Aug; 89(8):837-51. PubMed ID: 25042790
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2011 Nov; 86(11):928-48. PubMed ID: 21990092
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2016 Jan; 91(1):151-65. PubMed ID: 26607183
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2017 Oct; 92(10):1085-1102. PubMed ID: 28872191
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; A Wilcox R
Am J Hematol; 2021 Oct; 96(10):1313-1328. PubMed ID: 34297414
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2019 Sep; 94(9):1027-1041. PubMed ID: 31313347
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2023 Jan; 98(1):193-209. PubMed ID: 36226409
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
9. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
10. Mycosis Fungoides and Sézary Syndrome: An Update.
Larocca C; Kupper T
Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
[TBL] [Abstract][Full Text] [Related]
11. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
12. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
13. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
15. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
Devata S; Wilcox RA
Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
[TBL] [Abstract][Full Text] [Related]
17. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
19. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
20. Mycosis Fungoides and Sezary Syndrome.
Foss FM; Girardi M
Hematol Oncol Clin North Am; 2017 Apr; 31(2):297-315. PubMed ID: 28340880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
